Sanofi (XSWX:SAN) 3-Month Share Buyback Ratio: 0.00% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SAN Sanofi SA XSWX:SAN
91 GF Score
Price CHF73.20
GF Value CHF103.32
! 2 Warning Signs
View Full Analysis

What is Sanofi 3-Month Share Buyback Ratio?

Sanofi XSWX:SAN 91 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 91/100 and a GF Value™ of CHF103.32. The stock has 2 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

XSWX:SAN
91GF Score
Sanofi SA XSWX:SAN
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Sanofi (XSWX:SAN) has a 3-Month Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sanofi and its competitors.
Is Sanofi's 3-Month Share Buyback Ratio too high?
Sanofi's current 3-Month Share Buyback Ratio is 0.00. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's 3-Month Share Buyback Ratio compare to LLY and JNJ?
Sanofi's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Month Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sanofi and its competitors. Sanofi's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.

Key valuation signals for XSWX:SAN:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score

Get the complete analysis for XSWX:SAN

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF103.32
GF Value